- Home
- FAAS vs ANEB Comparison
FAAS vs ANEB Comparison
Compare FAAS & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAAS
- ANEB
- Stock Information
- Founded
- FAAS 2021
- ANEB 2020
- Country
- FAAS Indonesia
- ANEB United States
- Employees
- FAAS N/A
- ANEB N/A
- Industry
- FAAS
- ANEB Biotechnology: Pharmaceutical Preparations
- Sector
- FAAS
- ANEB Health Care
- Exchange
- FAAS NYSE
- ANEB Nasdaq
- Market Cap
- FAAS 34.6M
- ANEB 36.7M
- IPO Year
- FAAS N/A
- ANEB 2021
- Fundamental
- Price
- FAAS $0.26
- ANEB $0.97
- Analyst Decision
- FAAS
- ANEB Buy
- Analyst Count
- FAAS 0
- ANEB 1
- Target Price
- FAAS N/A
- ANEB $8.00
- AVG Volume (30 Days)
- FAAS 650.3K
- ANEB 18.9K
- Earning Date
- FAAS 01-01-0001
- ANEB 05-14-2025
- Dividend Yield
- FAAS N/A
- ANEB N/A
- EPS Growth
- FAAS N/A
- ANEB N/A
- EPS
- FAAS N/A
- ANEB N/A
- Revenue
- FAAS $57,730,593.00
- ANEB N/A
- Revenue This Year
- FAAS N/A
- ANEB N/A
- Revenue Next Year
- FAAS N/A
- ANEB N/A
- P/E Ratio
- FAAS N/A
- ANEB N/A
- Revenue Growth
- FAAS 38.16
- ANEB N/A
- 52 Week Low
- FAAS $0.20
- ANEB $0.80
- 52 Week High
- FAAS $10.63
- ANEB $3.20
- Technical
- Relative Strength Index (RSI)
- FAAS 36.10
- ANEB 37.94
- Support Level
- FAAS $0.19
- ANEB $0.95
- Resistance Level
- FAAS $0.24
- ANEB $1.10
- Average True Range (ATR)
- FAAS 0.05
- ANEB 0.11
- MACD
- FAAS 0.01
- ANEB -0.00
- Stochastic Oscillator
- FAAS 18.67
- ANEB 28.00
About FAAS DIGIASIA CORP
DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.